메뉴 건너뛰기




Volumn 55, Issue 10, 2014, Pages 1220-1227

Pharmacotherapy of solid tumors: New hopes and frustrations;Arzneitherapie solider Tumoren: Hoffnung und Frustration

Author keywords

Checkpoint inhibitors; Immunotherapy; Molecular targeted therapy; Sequential therapy; Tyrosine kinase inhibitors

Indexed keywords

ABIRATERONE; AFATINIB; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CABAZITAXEL; CRIZOTINIB; ENZALUTAMIDE; ERIBULIN; EVEROLIMUS; IMMUNOLOGICAL CHECKPOINT INHIBITOR; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RADIUM CHLORIDE RA 223; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VEMURAFENIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

EID: 84910106955     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-014-3553-3     Document Type: Article
Times cited : (2)

References (31)
  • 1
    • 84878375924 scopus 로고    scopus 로고
    • PID: 23725711, COI: 1:CAS:528:DC%2BC3sXosVOntL8%3D
    • Abou-Alfa GK, Venook AP (2013) The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol 14:e283–e288
    • (2013) Lancet Oncol , vol.14 , pp. e283
    • Abou-Alfa1
  • 2
    • 84901340078 scopus 로고    scopus 로고
    • PID: 24577748, COI: 1:CAS:528:DC%2BC2cXosFahsLY%3D
    • Ackerman A, Klein O, McDermott DF et al (2014) Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 120:1695–1701
    • (2014) Cancer , vol.120 , pp. 1695
    • Ackerman1
  • 3
    • 84868329937 scopus 로고    scopus 로고
    • PID: 22941024
    • Ang C, O’Reilly EM, Abou-Alfa GK (2013) Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res 190:225–246
    • (2013) Recent Results Cancer Res , vol.190 , pp. 225
    • Ang1
  • 4
    • 84899112560 scopus 로고    scopus 로고
    • PID: 24701370
    • Aranda F, Vacchelli E, Eggermont A et al (2014) Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 3:e27297
    • (2014) Oncoimmunology , vol.3 , pp. e27297
    • Aranda1
  • 5
    • 84887072136 scopus 로고    scopus 로고
    • PID: 23958310, COI: 1:CAS:528:DC%2BC3sXht12itbjF
    • Bahl A, Masson S, Birtle A et al (2014) Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 40:170–177
    • (2014) Cancer Treat Rev , vol.40 , pp. 170
    • Bahl1
  • 6
    • 84910132838 scopus 로고    scopus 로고
    • PID: 24685918, COI: 1:CAS:528:DC%2BC2cXlslSlsL8%3D
    • Bergmann L, Beck J, Bothe K et al (2014) Treatment algorithm for metastatic renal cell carcinoma – recommendations based on evidence and clinical practice. Oncol Res Treat 37:136–141
    • (2014) Oncol Res Treat , vol.37 , pp. 136
    • Bergmann1
  • 7
    • 84873864130 scopus 로고    scopus 로고
    • Brady D, Parker CC, O’Sullivan JM (2013) Bone-targeting radiopharmaceuticals including radium-223. Cancer J 19:71–78
    • (2013) Cancer , vol.J , pp. 71
    • Brady1
  • 8
    • 84878901004 scopus 로고    scopus 로고
    • PID: 23552469, COI: 1:CAS:528:DC%2BC3sXnvVKqsLc%3D
    • Buti S, Bersanelli M, Sikokis A et al (2013) Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 24:535–554
    • (2013) Anticancer Drugs , vol.24 , pp. 535
    • Buti1
  • 9
    • 84877824937 scopus 로고    scopus 로고
    • Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    • Chen YM (2013) Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J Chin Med Assoc 76:249–257
    • (2013) J Chin Med Assoc , vol.76 , pp. 249-257
    • Chen, Y.M.1
  • 10
    • 84879446651 scopus 로고    scopus 로고
    • PID: 23529824, COI: 1:CAS:528:DC%2BC3sXhvVWmtbjP
    • Dhillon S (2013) Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. Drugs 73:475–485
    • (2013) Drugs , vol.73 , pp. 475
    • Dhillon1
  • 11
    • 84898057419 scopus 로고    scopus 로고
    • COI: 1:CAS:528:DC%2BC2cXis1Sjsrk%3D
    • Freiwald M, Schmid U, Fleury A et al (2014) Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol 73:759–770
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 759
    • Freiwald1
  • 12
    • 84872921660 scopus 로고    scopus 로고
    • PID: 23177514, COI: 1:CAS:528:DC%2BC38Xhslarsr%2FE
    • Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312
    • (2013) Lancet , vol.381 , pp. 303
    • Grothey1
  • 13
    • 84864285704 scopus 로고    scopus 로고
    • PID: 22735384, COI: 1:CAS:528:DC%2BC38Xpt1SgtLg%3D
    • Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358–365
    • (2012) Lancet , vol.380 , pp. 358
    • Hauschild1
  • 14
    • 84895763109 scopus 로고    scopus 로고
    • PID: 24623990, COI: 1:CAS:528:DC%2BC2cXptVKhsbk%3D
    • Khan G, Moss RA, Braiteh F, Saltzman M (2014) Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. Cancer Manag Res 6:93–103
    • (2014) Cancer Manag Res , vol.6 , pp. 93
    • Khan1
  • 15
    • 84901324490 scopus 로고    scopus 로고
    • PID: 24749649
    • Kudlowitz D, Muggia F (2014) Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin Drug Saf 13:681–685
    • (2014) Expert Opin Drug Saf , vol.13 , pp. 681
    • Kudlowitz1
  • 16
    • 84892365940 scopus 로고    scopus 로고
    • PID: 24161671, COI: 1:CAS:528:DC%2BC3sXhsleru7vL
    • Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588:368–376
    • (2014) FEBS Lett , vol.588 , pp. 368
    • Kyi1
  • 17
    • 84892175976 scopus 로고    scopus 로고
    • PID: 24266804, COI: 1:CAS:528:DC%2BC2cXptFarsg%3D%3D
    • Martin-Liberal J, Benson C, Judson I (2014) New drugs in sarcomas. Expert Opin Pharmacother 15:221–229
    • (2014) Expert Opin Pharmacother , vol.15 , pp. 221
    • Martin-Liberal1
  • 18
    • 84901605959 scopus 로고    scopus 로고
    • Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis
    • Maute L, Grunwald V, Weikert S et al (2014) Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol 140:823–827
    • (2014) J Cancer Res Clin Oncol , vol.140 , pp. 823-827
    • Maute, L.1    Grunwald, V.2    Weikert, S.3
  • 19
    • 84896714827 scopus 로고    scopus 로고
    • PID: 24508103, COI: 1:CAS:528:DC%2BC2cXisFersrg%3D
    • McArthur GA, Chapman PB, Robert C et al (2014) Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323–332
    • (2014) Lancet Oncol , vol.15 , pp. 323
    • McArthur1
  • 20
    • 84884721380 scopus 로고    scopus 로고
    • PID: 23942774, COI: 1:STN:280:DC%2BC3sfpsVanuw%3D%3D
    • McDermott D, Haanen J, Chen TT et al (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010–20). Ann Oncol 24:2694–2698
    • (2013) Ann Oncol , vol.24 , pp. 2694
    • McDermott1
  • 21
    • 84883021976 scopus 로고    scopus 로고
    • PID: 23560546, COI: 1:CAS:528:DC%2BC3sXhtlalt7jO
    • Mouhayar E, Durand JB, Cortes J (2013) Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf 12:687–696
    • (2013) Expert Opin Drug Saf , vol.12 , pp. 687
    • Mouhayar1
  • 22
    • 84873974299 scopus 로고    scopus 로고
    • O’Bryant CL, Wenger SD, Kim M, Thompson LA (2013) Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. Ann Pharmacother 47:189–197
    • (2013) Ann Pharmacother , vol.47 , pp. 189
    • O1
  • 23
    • 84886443514 scopus 로고    scopus 로고
    • PID: 24089443, COI: 1:CAS:528:DC%2BC3sXhsFyns7bM
    • Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19:5300–5309
    • (2013) Clin Cancer Res , vol.19 , pp. 5300
    • Ott1
  • 24
    • 84885101825 scopus 로고    scopus 로고
    • PID: 23658121, COI: 1:CAS:528:DC%2BC3sXhsl2nsbzL
    • Saji S (2013) Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane. BioDrugs 27:469–478
    • (2013) BioDrugs , vol.27 , pp. 469
    • Saji1
  • 25
    • 84906929620 scopus 로고    scopus 로고
    • PID: 24756806
    • Schulze M, Stock C, Zaccagnini M et al (2014) Temsirolimus. Recent Results Cancer Res 201:393–403
    • (2014) Recent Results Cancer Res , vol.201 , pp. 393
    • Schulze1
  • 26
    • 84895459037 scopus 로고    scopus 로고
    • Sebastian M, Schmittel A, Reck M (2014) First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. Euro Res Rev 23:92–105
    • (2014) Euro Res Rev , vol.23 , pp. 92
    • Sebastian1
  • 27
    • 84898994085 scopus 로고    scopus 로고
    • PID: 24790651, COI: 1:CAS:528:DC%2BC2cXhs1Okur%2FE
    • Serrano C, George S (2014) Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 6:115–127
    • (2014) Ther Adv Med Oncol , vol.6 , pp. 115
    • Serrano1
  • 28
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
    • (2012) N Engl J Med , vol.366 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    al, B.J.R.3
  • 29
    • 84899115962 scopus 로고    scopus 로고
    • PID: 24605265
    • Vacchelli E, Aranda F, Eggermont A et al (2014) Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 3:e27048
    • (2014) Oncoimmunology , vol.3 , pp. e27048
    • Vacchelli1
  • 30
    • 84886741654 scopus 로고    scopus 로고
    • Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
    • Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703
    • (2013) N Engl J Med , vol.369 , pp. 1691-1703
    • Von Hoff, D.D.1    Ervin, T.2    al, A.F.P.3
  • 31
    • 84880054782 scopus 로고    scopus 로고
    • PID: 23774698, COI: 1:CAS:528:DC%2BC3sXpvVOks7g%3D
    • Zagouri F, Sergentanis TN, Chrysikos D et al (2013) Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. Pancreas 42:760–773
    • (2013) Pancreas , vol.42 , pp. 760
    • Zagouri1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.